AniClin Preclinical Services (“AniClin”), specializing in in vivo services to support early drug development activities, is now offering complete pharmacokinetic (PK) studies in less than five days. This quick turnaround service comes after entering a strategic alliance with Taylor Technology, a subsidiary of PharmaNet Development Group, which specializes in supporting bioanalytical programs of any size from Discovery to Phase IV.
The PK package offers formulation, dosing, PK sampling, bioanalysis (plasma) of 6 timepoints, inclusive of quality control samples and front and back standard curves, all in less than 5 days. AniClin and Taylor Technology work seamlessly to meet this Fast PK timeline which involves the NCE arriving at AniClin where dosing is performed and plasma samples are collected. The samples are then delivered to Taylor Technology within two hours. The plasma samples are immediately processed upon receipt for development of non-GLP bioanalytical protocols, data analysis and estimation of PK parameters. The data and PK estimates are then emailed to the sponsor.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
SCOPE Summit 2025: Enhancing the Patient Experience Through Site Centricity
February 12th 2025In an interview with ACT senior editor Andy Studna at SCOPE Summit, Ashley Davidson, vice president, product lead - sponsor tech strategy, Advarra, highlights the need for more site-centric approaches in study startup.